Background pattern

FLUAD SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use FLUAD SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE

Introduction

Package Leaflet: Information for the User

Fluad injectable suspension in a pre-filled syringe

Influenza vaccine (surface antigen, inactivated, with adjuvant)

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the package leaflet

  1. What is Fluad and what is it used for
  2. What you need to know before you are given Fluad
  3. How Fluad is given
  4. Possible side effects
  5. Storage of Fluad
  6. Contents of the pack and other information

1. What is Fluad and what is it used for

Fluad is an influenza vaccine.

When a person is given the vaccine, the immune system (the body's natural defense system) will produce its own protection against the influenza virus. None of the components of the vaccine can cause influenza.

Fluad is used to prevent influenza in people aged 50 years and over.

The vaccine is aimed at the strains of the influenza virus following the recommendations of the World Health Organization for the 2025/2026 campaign.

2. What you need to know before you are given Fluad

You should not be given Fluad

  • if you are allergic to:
  • the active substances or any of the other ingredients of this medicine (listed in section 6).
  • egg or chicken proteins (such as ovalbumin), kanamycin, and neomycin sulfate, formaldehyde, cetyltrimethylammonium bromide (CTAB), and hydrocortisone, which are residues of the manufacturing process that may be present in minimal amounts.
  • If you have had a severe allergic reaction (e.g., anaphylaxis) to a previous influenza vaccine.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before you are given Fluad.

BEFORE vaccination

  • your doctor or nurse will check that medical treatment and adequate supervision are readily available in case of a rare anaphylactic reaction (a very severe allergic reaction with symptoms such as difficulty breathing, dizziness, weak and rapid pulse, and skin rash) after administration. This reaction can occur with Fluad, as with all injectable vaccines.
  • you should inform your doctor if you have a disease with fever. Your doctor may decide to delay your vaccination until the fever has disappeared.
  • you should inform your doctor if your immune system is compromised or if you are receiving treatment that affects it, for example, cancer medication (chemotherapy) or corticosteroids (see section "Other medicines and Fluad").
  • you should inform your doctor if you have a bleeding problem or if you bruise easily.
  • you may faint after injection with a needle, or even before, therefore inform your doctor or nurse if you have fainted previously with any injection.

As with all vaccines, Fluad may not completely protect all people who are vaccinated.

Children

Fluad is not recommended for use in children.

Other medicines and Fluad

Tell your doctor or nurse if you are using, have recently used, or might use any other medicines, including those obtained without a prescription, or if you have recently received any other vaccine.

Pregnancy and breastfeeding

This vaccine is intended for adults aged 50 years and over. It should not be used in women who are or may be pregnant, or during breastfeeding.

Driving and using machines

Fluad has no or negligible influence on the ability to drive and use machines.

Fluad contains potassium and sodium

This vaccine contains less than 1 mmol of sodium (23 mg) per dose; this is, essentially "sodium-free".

This vaccine contains potassium, less than 1 mmol (39 mg) per dose; this is, essentially "potassium-free".

3. How Fluad is given

Your doctor or nurse will give you Fluad as an injection into the muscle of the upper arm (deltoid muscle).

Adults aged 50 years and over:

A dose of 0.5 ml

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or go to the emergency department of your nearest hospital immediately if you experience the following serious side effects, as you may need urgent medical attention or hospitalization:

  • Difficulty breathing, dizziness, weak and rapid pulse, and skin rash, which are symptoms of an anaphylactic reaction (a very severe allergic reaction)

The following side effects have been reported during clinical trials in adults aged 50 years and over.

Very common (may affect more than 1 in 10 people):

  • Pain or tenderness at the injection site
  • Fatigue
  • Headache
  • Joint pain (arthralgia)1
  • Muscle pain (myalgia)1

1 Reported as frequent in elderly subjects aged 65 years and over.

Common (may affect up to 1 in 10 people):

  • Redness at the injection site (erythema)
  • Hardening of the skin at the injection site (induration)
  • Diarrhea
  • Chills
  • Nausea
  • Loss of appetite
  • Bruising at the injection site (ecchymosis)
  • Flu-like symptoms2
  • Fever (≥38 °C)3

2 Reported in elderly subjects aged 65 years and over.

3 Reported as uncommon in elderly subjects aged 65 years and over.

Uncommon (may affect up to 1 in 100 people):

  • Vomiting
  • Swelling of the lymph nodes in the neck, armpit, or groin (lymphadenopathy)

Most side effects were mild or moderate and disappeared within 3 days of onset.

In addition to the side effects mentioned, the following side effects have occasionally occurred during general use of the quadrivalent influenza vaccine or Fluad.

  • reduction in the number of a certain type of particle in the blood called platelets; a low number of these can cause bruising or bleeding (thrombocytopenia)
  • swelling, pain, and redness at the injection site (reaction similar to cellulitis at the injection site)
  • extensive swelling of the limb where the medicine was injected, lasting more than one week.
  • general weakness or lack of energy (asthenia), feeling unwell (malaise)
  • fever (pyrexia)
  • muscle weakness
  • pain in the nerve pathway (neuralgia), unusual sensation of touch, pain, heat, and cold (paresthesia), seizures (convulsions), neurological disorders that can cause stiffness of the neck, confusion, numbness, pain, and weakness of the limbs, loss of balance, loss of reflexes, paralysis of part or all of the body (encephalomyelitis, neuritis, Guillain-Barré syndrome)
  • skin reactions that can spread throughout the body, such as itching of the skin (pruritus, urticaria), redness of the skin (erythema), non-specific rash, severe skin rash (erythema multiforme)
  • more pronounced swelling of the face, lips, tongue, throat, or any other part of the body (angioedema)
  • swelling of the blood vessels that can cause skin rashes (vasculitis) and temporary kidney problems
  • fainting, feeling of being about to faint (syncope, presyncope)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that the side effects are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Fluad

Keep this medicine out of the sight and reach of children.

Store in a refrigerator (between 2 °C and 8 °C). Do not freeze. Discard if the vaccine has been frozen. Keep the pre-filled syringe in the outer packaging to protect it from light.

Do not use this vaccine after the expiry date which is stated on the label and on the carton after EXP/CAD. The expiry date is the last day of the month stated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

Composition of Fluad

  • The active substances are surface antigens of the influenza virus (hemagglutinin and neuraminidase), inactivated, of the following strains*:

Per 0.5 ml dose

Strain similar to A/Victoria/4897/2022

(H1N1)pdm09

(A/Victoria/4897/2022, IVR-238)

15 micrograms HA**

Strain similar to A/Croatia/10136RV/2023 (H3N2)

(A/Croatia/10136RV/2023, X-425A)

15 micrograms HA**

Strain similar to B/Austria/1359417/2021

(B/Austria/1359417/2021, BVR-26)

15 micrograms HA**

*propagated in embryonated chicken eggs from healthy chicken flocks and adjuvanted with MF59C.1

**hemagglutinin

This vaccine complies with the recommendation of the World Health Organization (WHO) (northern hemisphere) and with the EU recommendation for the 2025/2026 season.

  • This vaccine includes MF59C.1 as an adjuvant. Adjuvants are substances included in certain vaccines to accelerate, improve, or prolong the protective effects of the vaccine. MF59C.1 is an adjuvant that contains per 0.5 ml dose: squalene (9.75 mg), polysorbate 80 (1.175 mg), sorbitan trioleate (1.175 mg), sodium citrate (0.66 mg), and citric acid (0.04 mg).
  • The other ingredients are sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, and water for injections.

Appearance of the product and pack contents

Fluad is an injectable suspension in a pre-filled syringe. Fluad is a white, cloudy suspension. Each pre-filled syringe contains a single dose (0.5 ml) of injectable suspension. Fluad is available in packs containing 1 or 10 pre-filled syringes with or without needles.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Seqirus Netherlands B.V.

Paasheuvelweg 28, 1105 BJ Amsterdam, Netherlands

For further information about this medicine, contact the local representative of the marketing authorisation holder:

Belgium/Belgique/Belgien

Seqirus Netherlands

B.V.Nederland/Netherlands

Tel: +31 (0) 20 204 6900

Lithuania

Seqirus Netherlands B.V. Nyderlandai

Tel: +31 (0) 20 204 6900

Text in a foreign language with contact information of a company in the Netherlands including address and phone number

Luxembourg/Luxemburg

Seqirus Netherlands B.V. Netherlands

Tél/Tel: +31 (0) 20 204 6900

Czech Republic

Seqirus Netherlands B.V. Nizozemsko

Tel: +31 (0) 20 204 6900

Hungary

Seqirus Netherlands B.V. Hollandia

Tel.: +31 (0) 20 204 6900

Denmark

Seqirus Netherlands B.V. Holland

Tlf: +31 (0) 20 204 6900

Malta

Seqirus Netherlands B.V. In-Netherlands

Tel: +31 (0) 20 204 6900

Germany

Seqirus GmbH Marburg

Tel: 0800/3601010

Netherlands

Seqirus Netherlands B.V. Amsterdam

Tel: +31 (0) 20 204 6900

Estonia

Seqirus Netherlands B.V. Holland

Tel: +31 (0) 20 204 6900

Norway

Seqirus Netherlands B.V. Nederland

Tlf: +31 (0) 20 204 6900

Text with the company name WIN MEDICA A E and phone number 210 7488821 in black letters

Austria

Valneva Austria GmbH, Wien

Tel: +43 1 20620 2020

Spain

Seqirus Spain S.L. Barcelona

Tel 937 817 884

Poland

Seqirus Netherlands B.V. Holandia

Tel.: +31 (0) 20 204 6900

France

Seqirus Netherlands B.V. Netherlands

Tél: +31 (0) 20 204 6900

Portugal

Seqirus Netherlands B.V. Países Baixos

Tel: +31 (0) 20 204 6900

Croatia

Seqirus Netherlands B.V. Nizozemska

Tel: +31 (0) 20 204 6900

Romania

Seqirus Netherlands B.V. Olanda

Tel: +31 (0) 20 204 6900

Ireland

Seqirus UK Limited Maidenhead

Tel: +44 1628 641 500

Slovenia

Seqirus Netherlands B.V. Nizozemska

Tel: +31 (0) 20 204 6900

Iceland

Seqirus Netherlands B.V. Holland

Sími: +31 (0) 20 204 6900

Slovakia

Seqirus Netherlands B.V. Holandsko

Tel: +31 (0) 20 204 6900

Italy

Seqirus S.r.l. Siena

Tel: +39 0577 096400

Finland

Seqirus Netherlands B.V. Alankomaat

Puh/Tel: +31 (0) 20 204 6900

Text in Greek and Dutch with contact information of Seqirus Netherlands BV including phone number

Sweden

Seqirus Netherlands B.V. Nederländerna

Tel: +31 (0) 20 204 6900

Latvia

Seqirus Netherlands B.V. Niderlande

Tel: +31 (0) 20 204 6900

Date of last revision of this leaflet: 07/2025.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

-----------------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Medical treatment and adequate supervision should always be readily available in case of an anaphylactic episode, which can rarely occur after vaccine administration.

Shake gently before use. After shaking, the normal appearance of the vaccine is a white, cloudy suspension.

The vaccine should be inspected visually for particulate matter and color changes before administration. If particulate matter and/or any variation of the physical appearance is observed, do not administer the vaccine.

If a pre-filled syringe without a needle is used, the protective cap should be removed from the tip of the syringe and a needle should be attached for administration. A sterile needle of suitable size should be used for intramuscular injection. For LuerLock syringes, remove the protective cap from the tip of the syringe by unscrewing it in an anticlockwise direction. Once the protective cap has been removed, attach a needle to the syringe by screwing it in a clockwise direction until it is secure. When the needle is securely in place, remove the needle protector and administer the vaccine.

Get updates and exclusive offers

Be the first to know about new services, marketplace updates, and subscriber-only promos.

Follow us on social media
FacebookInstagram
Logo
Oladoctor
Find a doctor
Doctors by specialty
Services
Choose language
© 2025 Oladoctor. All rights reserved.
VisaMastercardStripe